Precision diagnostics company Oncocyte on Friday announced the publication of results from the randomized phase II AtezoTRIBE clinical trial for metastatic colorectal cancer (mCRC), which used the company’s DetermaIO gene-expression test.
The results, published in Clinical Cancer Research, show that DetermaIO, which assesses the tumor microenvironment to predict response to immune checkpoint inhibitor (ICI) treatment, identified more patients who were potentially responsive to ICI treatment than current biomarkers.